King's College London

Research portal

Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate

Research output: Contribution to journalArticlepeer-review

L. Hamzah, S. Jose, J. W. Booth, A. Hegazi, M. Rayment, A. Bailey, D. I. Williams, B. M. Hendry, P. Hay, R. Jones, J. B. Levy, D. R. Chadwick, M. Johnson, C. A. Sabin, F. A. Post

Original languageEnglish
JournalThe Journal of infection
Early online date25 Jan 2017
DOIs
Accepted/In press17 Jan 2017
E-pub ahead of print25 Jan 2017

Documents

King's Authors

Abstract

Objectives: Tenofovir disoproxil fumarate (TDF) is widely used in the treatment or prevention of HIV and hepatitis B infection. TDF may cause renal tubulopathy in a small proportion of recipients. We aimed to study the risk factors for developing severe renal tubulopathy. Methods: We conducted an observational cohort study with retrospective identification of cases of treatment-limiting tubulopathy during TDF exposure. We used multivariate Poisson regression analysis to identify risk factors for tubulopathy, and mixed effects models to analyse adjusted estimated glomerular filtration rate (eGFR) slopes. Results: Between October 2002 and June 2013, 60 (0.4%) of 15,983 patients who had received TDF developed tubulopathy after a median exposure of 44.1 (IQR 20.4, 64.4) months. Tubulopathy cases were predominantly male (92%), of white ethnicity (93%), and exposed to antiretroviral regimens that contained boosted protease inhibitors (PI, 90%). In multivariate analysis, age, ethnicity, CD4 cell count and use of didanosine or PI were significantly associated with tubulopathy. Tubulopathy cases experienced significantly greater eGFR decline while receiving TDF than the comparator group (-6.60 [-7.70, -5.50] vs. -0.34 [-0.43, -0.26] mL/min/1.73 m2/year, p <0.0001). Conclusions: Older age, white ethnicity, immunodeficiency and co-administration of ddI and PI were risk factors for tubulopathy in patients who received TDF-containing antiretroviral therapy. The presence of rapid eGFR decline identified TDF recipients at increased risk of tubulopathy.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454